ClinicalTrials.gg
TerminatedNCT01283386Updated Mar 14, 2019Results posted

A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status

A Phase 4 interventional study of Chlorambucil and Cyclophosphamide in Lymphocytic Leukemia, Chronic, sponsored by Hoffmann-La Roche. Terminated at 8 sites in Russian Federation. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2019-03-14.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 11 under way, none of them phase 3. Cyclophosphamide · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
104th of 145
26 · median 49
Started
2011
with 7 others
Phase 4
3 of 155
none open now
Registered
112th of 155
by date
Lead sponsor
7 of 155
Hoffmann-La Roche

Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 104th largest by enrollment of the 145 interventional ones that give a count, is one of 8 that started in 2011, is one of 3 in phase 4, and was the 112th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

3 of the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This multi-center, randomized study compared the efficacy and safety of MabThera (rituximab) in combination with either fludarabine and cyclophosphamide or with chlorambucil in participants with previously untreated B-cell chronic lymphocytic leukemia and unfavorable somatic status. Participants were randomized to receive Mabthera (375 mg/m2 intravenously [IV] Day 1 of Cycle 1, 500 mg/m2 IV Day 1 Cycles 2-6) with either fludarabine (20 mg/m2 IV or 32 mg/m2 orally Days 1-3) and cyclophosphamide (150 mg/m2 IV or orally Days 1-3) or with chlorambucil (10 mg/m2 orally Days 1-7) for 6 cycles of 28 days. Anticipated time on study treatment was 24 weeks.

03

Conditions studied

  • Lymphocytic Leukemia, Chronic
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, 60-70 or >70 years of age
  • Cumulative Illness Rating Scale (CIRS) comorbidity score >/=7 if patient is 60-70 years old
  • Previously untreated B-cell chronic lymphocytic leukemia
  • Binet stage B, C or A with progression
  • performance status 0-2

Exclusion criteria

Exclusion Criteria:

  • Small-cell lymphoma
  • hemolytic anemia
  • Concomitant malignant disease during enrollment, except for basal cell carcinoma of the skin
  • Chemotherapy for concomitant malignant disease within 12 months prior to study enrollment
  • Richter's syndrome
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    FCR-lite

    Rituximab, fludarabine, and cyclophosphamide

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Rituximab

  • Active comparator
    LR Therapy

    Rituximab and chlorambucile

    Drug: Chlorambucil · Drug: Rituximab

Interventions

  • 10 mg/m\^2 orally on Days 1-7 of each 28-day cycle for 6 cycles

  • 150 mg/m\^2 IV or orally on Days 1-3 of each 28-day cycle for 6 cycles

  • 20 mg/m\^2 IV or 32 mg/m2 orally Days 1-3 of each 28-day cycle for 6 cycles

  • 375 mg/m2 IV on Day 1 of Cycle 1; 500 mg/m2 IV on Day 1 of Cycles 2-6 (28-day cycles)

    Also known as: MabThera

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Complete Remission

    Complete remission was defined as the disappearance of all signs of disease.

    Time frame: Up to approximately 5 years

  2. Percentage of Participants With Disease Progression

    Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen.

    Time frame: Up to approximately 5 years

  3. Percentage of Participants With Stable Disease

    Stable disease was defined as not meeting the criteria for partial remission or disease progression

    Time frame: Up to approximately 5 years

  4. Percentage of Participants With Partial Remission

    Partial remission was defined as a reduction in tumor size by \>50%.

    Time frame: Up to approximately 5 years

  5. Duration of Response

    Duration of Response was defined as the time period from the last day of study treatment to the day when disease progression occurred in participants who previously had complete or partial remission. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. Complete remission was defined as the disappearance of all signs of disease. Partial remission was defined as a reduction in tumor size by \>50%.

    Time frame: Up to approximately 5 years

  6. Progression-free Survival

    Progression-free survival was defined as the time period from the first day of study treatment to the day when disease progression occurred. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen.

    Time frame: Up to approximately 5 years

  7. Event-free Survival

    Event-free survival was defined as the time period from the first day of study treatment to occurrence of any of the following events: appearance of disease progression or relapse; prescription of a new treatment for disease relapse; death caused by B-cell chronic lymphocytic leukemia (B-CLL); or complications from B-CLL or therapy. Relapse was defined as disease progression in participants with complete or partial remission lasting at least 6 months after treatment completion. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. Complete remission was defined as the disappearance of all signs of disease. Partial remission was defined as a reduction in tumor size by \>50%.

    Time frame: Up to approximately 5 years

  8. Overall Survival

    Overall survival was defined as the time period from the first day of study treatment to participant death.

    Time frame: Up to approximately 5 years

  9. Percentage of Participants With Phenotypic Remission

    Phenotypic remission was considered achieved if a participant had a negative test for minimal residual disease. A negative test for minimal residual disease was defined as tumor cells ≤0.01% of the total number of peripheral leukocytes.

    Time frame: Up to approximately 5 years

  10. Percentage of Participants With Adverse Events (AEs) and Serious AEs

    An AE was defined as any unfavorable medical occurrence in a participant receiving a study drug, regardless of relationship the study drug. An AE was considered serious if it met any of the following criteria: was fatal or life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was clinically significant and/or required an intervention to prevent any of the listed criteria.

    Time frame: Up to approximately 5 years

07

Results

Posted Mar 14, 2019

Participant flow

Participant flow — Overall Study
MilestoneFCR-liteLR Therapy
Started1016
Completed24
Not completed812
Withdrew: Death20
Withdrew: Withdrawal by subject21
Withdrew: Relapse of underlying disease13
Withdrew: Progression of underlying disease27
Withdrew: Reason not specified10
Withdrew: Protocol violation01

Outcome measures

PrimaryPercentage of Participants With Complete Remission

Complete remission was defined as the disappearance of all signs of disease.

Time frame:
Up to approximately 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Remission
percentage of participantsFCR-liteLR Therapy
Percentage of Participants With Complete Remission42.918.8
PrimaryPercentage of Participants With Disease Progression

Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen.

Time frame:
Up to approximately 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Progression
percentage of participantsFCR-liteLR Therapy
Percentage of Participants With Disease Progression06.3
PrimaryPercentage of Participants With Stable Disease

Stable disease was defined as not meeting the criteria for partial remission or disease progression

Time frame:
Up to approximately 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Stable Disease
percentage of participantsFCR-liteLR Therapy
Percentage of Participants With Stable Disease14.318.8
PrimaryPercentage of Participants With Partial Remission

Partial remission was defined as a reduction in tumor size by \>50%.

Time frame:
Up to approximately 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Partial Remission
percentage of participantsFCR-liteLR Therapy
Percentage of Participants With Partial Remission42.956.3
PrimaryDuration of Response

Duration of Response was defined as the time period from the last day of study treatment to the day when disease progression occurred in participants who previously had complete or partial remission. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. Complete remission was defined as the disappearance of all signs of disease. Partial remission was defined as a reduction in tumor size by \>50%.

Time frame:
Up to approximately 5 years
Reported as:
Median · days
Duration of Response
daysFCR-liteLR Therapy
Duration of ResponseNA (NA to NA)NA (NA to NA)
PrimaryProgression-free Survival

Progression-free survival was defined as the time period from the first day of study treatment to the day when disease progression occurred. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen.

Time frame:
Up to approximately 5 years
Reported as:
Median · days
Progression-free Survival
daysFCR-liteLR Therapy
Progression-free SurvivalNA (NA to NA)NA (NA to NA)
PrimaryEvent-free Survival

Event-free survival was defined as the time period from the first day of study treatment to occurrence of any of the following events: appearance of disease progression or relapse; prescription of a new treatment for disease relapse; death caused by B-cell chronic lymphocytic leukemia (B-CLL); or complications from B-CLL or therapy. Relapse was defined as disease progression in participants with complete or partial remission lasting at least 6 months after treatment completion. Disease progression was defined as an increase in lymphocytosis, or enlargement of the lymph nodes or spleen. Complete remission was defined as the disappearance of all signs of disease. Partial remission was defined as a reduction in tumor size by \>50%.

Time frame:
Up to approximately 5 years
Reported as:
Median · days
Event-free Survival
daysFCR-liteLR Therapy
Event-free Survival679 (14.00 to NA)NA (NA to NA)
PrimaryOverall Survival

Overall survival was defined as the time period from the first day of study treatment to participant death.

Time frame:
Up to approximately 5 years
Reported as:
Median · days
Overall Survival
daysFCR-liteLR Therapy
Overall SurvivalNA (NA to NA)NA (NA to NA)
PrimaryPercentage of Participants With Phenotypic Remission

Phenotypic remission was considered achieved if a participant had a negative test for minimal residual disease. A negative test for minimal residual disease was defined as tumor cells ≤0.01% of the total number of peripheral leukocytes.

Time frame:
Up to approximately 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Phenotypic Remission
percentage of participantsFCR-liteLR Therapy
Percentage of Participants With Phenotypic Remission25.030.0
PrimaryPercentage of Participants With Adverse Events (AEs) and Serious AEs

An AE was defined as any unfavorable medical occurrence in a participant receiving a study drug, regardless of relationship the study drug. An AE was considered serious if it met any of the following criteria: was fatal or life-threatening; required hospitalization or prolonged hospitalization; led to persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was clinically significant and/or required an intervention to prevent any of the listed criteria.

Time frame:
Up to approximately 5 years
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious AEs
percentage of participantsFCR-liteLR Therapy
Non-serious AEs80.0056.25
Serious AEs20.0018.75

Adverse events

Collected over Up to approximately 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FCR-lite—2/10 (20%)8/10 (80%)
LR Therapy—3/16 (18.8%)9/16 (56.3%)
Most frequent serious events
Most frequent serious events
EventFCR-liteLR Therapy
DeathGeneral disorders2/100/16
Acute myocardial infarctionVascular disorders1/100/16
Retroperitoneal abscessInfections and infestations0/101/16
Benign prostatic hyperplasiaReproductive system and breast disorders0/101/16
PneumoniaRespiratory, thoracic and mediastinal disorders0/101/16
Most frequent other events
Showing 10 of 20
Most frequent other events
EventFCR-liteLR Therapy
Neutrophil count decreasedInvestigations2/102/16
BronchitisRespiratory, thoracic and mediastinal disorders2/101/16
PyrexiaGeneral disorders2/100/16
White blood cell count decreasedInvestigations1/102/16
Blood bilirubin increasedInvestigations1/100/16
Glomerular filtration rateInvestigations1/100/16
Cardiac failure acuteCardiac disorders1/100/16
ThrombocytopeniaBlood and lymphatic system disorders1/100/16
NauseaGastrointestinal disorders1/100/16
Renal colicRenal and urinary disorders1/100/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)FCR-liteLR TherapyTotal
Mean68.7 ± 7.0968.6 ± 4.9568.6 ± 5.73
Sex: Female, Male
Sex: Female, Male(Participants)FCR-liteLR TherapyTotal
Female3710
Male7916
08

Study locations

8 sites
  • The order of Honour pin Irkutsk regional clinical hospital; Hematology Department
    Irkutsk, 664079, Russian Federation
  • Kemerovo Regional Clinical Hospital
    Kemerovo, 650066, Russian Federation
  • N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis
    Moscow, 115478, Russian Federation
  • City Clinical Botkin's Hospital; City Hematological Center
    Moscow, 125284, Russian Federation
  • City Clinical Hospital #15; Hematology department
    Saint-Petersburg, 198205, Russian Federation
  • Saint-Petersburg SHI City Clinical Hospital #31
    St. Petersburg, 197110, Russian Federation
  • GUZ Tula Regioanal Clinical Hospital; Hematology
    Tula, 300053, Russian Federation
  • Republican clinical hospital named after G.G. Kuvatov
    UFA, 450005, Russian Federation
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2011 to primary completion in Mar 2016, 58 months.

Results were first posted in Mar 2019, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2011
First posted
Jan 26, 2011
StartActual
Apr 27, 2011
Primary completionActual
Mar 16, 2016
CompletionActual
Mar 16, 2016
Results first posted
Mar 14, 2019
Last update
Mar 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01283386
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 26, 2011
Start date
Apr 27, 2011
Primary completion
Mar 16, 2016
Completion
Mar 16, 2016
Results posted
Mar 14, 2019
Last update
Mar 14, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Fludarabine

Start the discussion